INREBIC vs JAKAFI XR

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated June 7, 2026·How we rate

Possible drug interaction. INREBIC and JAKAFI XR are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	INREBIC	JAKAFI XR
Rating	New	New
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	FEDRATINIB HYDROCHLORIDE	RUXOLITINIB PHOSPHATE
Manufacturer	Bristol-Myers	Incyte Corp
Dosage forms	Capsule	Tablet, extended release
Drug class	—	Janus Kinase Inhibitor
Boxed warning	None	None
Treats	Primary Myelofibrosis	Polycythemia Vera, Primary Myelofibrosis

inrebic jakafi xr

Rating

New

Pharmacy pays

—

Type

Active ingredient

FEDRATINIB HYDROCHLORIDE

RUXOLITINIB PHOSPHATE

Manufacturer

Bristol-Myers

Incyte Corp

Dosage forms

Capsule

Tablet, extended release

Drug class

—

Janus Kinase Inhibitor

Boxed warning

None

Treats

Primary Myelofibrosis

Polycythemia Vera, Primary Myelofibrosis

Frequently asked questions

What is the difference between Inrebic and Jakafi XR?

Inrebic contains Fedratinib Hydrochloride, while Jakafi XR contains Ruxolitinib Phosphate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.